Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials

Meredith A. Mortberg1,2, Sonia M. Vallabh1,2 & Eric Vallabh Minikel1,2*

Neurodegenerative disease is increasingly prevalent and remains without disease-modifying therapies. Engaging the right target, at the right disease stage, could be an important determinant of success. We annotated targets and eligibility criteria for 3238 neurodegenerative disease trials registered at ClinicalTrials.gov from 2000 to 2020. Trials became more selective as the mean number of inclusion and exclusion criteria increased and eligible score ranges shrank. Despite a shift towards less impaired participants, only 2.7% of trials included pre-symptomatic individuals; these were depleted for drug trials and enriched for behavioral interventions. Sixteen novel, genetically supported therapeutic hypotheses tested in drug trials represent a small, non-increasing fraction of trials, and the mean lag from genetic association to first trial was 13 years. Though often linked to disease initiation, not progression, these targets were tested mostly at symptomatic disease stages. The potential for disease modification through early intervention against root molecular causes of disease remains largely unexplored.

Neurodegenerative disease is on the rise globally due to aging populations1, highlighting a need for effective therapeutic interventions. Developing new drugs is incredibly difficult, with only 8–14% of all drug-indication pairs that enter clinical trials ultimately succeeding2–4. Success has been particularly limited in adult-onset neurodegenerative diseases, for which no disease-modifying drug yet exists. Patients, scientists, regulators, and public health experts have called for prioritizing preventive approaches to neurodegeneration, citing potential benefits to quality of life and alleviation of economic burden, as well as improved prospects for success if intervention against core molecular drivers of disease occurs before downstream pathology takes hold5–10. Yet there exist considerable barriers to achieving prevention, including the potential cost and duration of trials, need for deeper validation of biomarker endpoints, and the requirement for careful protections and counseling of at-risk subjects in trials5,7,11.

In this study, we sought to understand the disease stages and therapeutic hypotheses studied in clinical trials conducted in neurodegenerative diseases to date. Current drug development pipelines have been catalogued elsewhere12–15, but we found that none of these reports answered our key questions. First, experimental drugs are often broadly categorized as “disease-modifying” if the hypothesis is one of disease modification, regardless of the quality of that hypothesis. We wished to examine the share of drugs with molecular targets underpinned by human genetic associations, which can inform drug development strategy16 and have been shown empirically to double success rates in drug development17,18. Second, while reports sometimes categorize trials as preventive versus symptomatic, we wished to examine more quantitative metrics of disease stage or severity. Third, while snapshots of the present pipeline are illuminating, we sought a longitudinal view of drug discovery over the past 2 decades. Finally, prior studies did not make their full datasets publicly available to facilitate re-analysis. Therefore, combining automated annotation and deep manual curation of clinical trial registrations from ClinicalTrials.gov, we set out to map the landscape of clinical trials and their therapeutic interventions and to test correlations and trends over the past 2 decades.

1McCance Center for Brain Health and Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA. 2Stanley Center for Psychiatric Research, Broad Institute, Cambridge, MA 02142, USA. *email: eminikel@broadinstitute.org
Methods

Study design. Our goals were to characterize clinical trials across major neurodegenerative disease indications, identifying correlations and temporal trends, particularly with regards to disease stages and molecular targets of drugs. We chose ClinicalTrials.gov as a data source because (i) it is publicly available, allowing us to release our reviewed and annotated dataset and source code and thus make our analyses fully reproducible, (ii) it has existed since 2000, thus providing 2 decades of data, and (iii) compliance with Food and Drug Administration Amendments Act (FDAAA) mandates have made it a fairly comprehensive listing of trials\(^\text{19,20}\). Trial results are not always posted or published in a timely fashion\(^\text{21-23}\), but our analysis focused on the design, not results, of trials. We determined that the ClinicalTrials.gov data, downloadable in XML format, necessitated a hybrid approach using both scripting and manual curation. Some variables, such as study start and end dates, enrollment, and phase are captured in specific fields and can be trivially extracted with scripts. Other variables require manual curation either because they are described using variable diction within free text fields (eligibility criteria), contain large numbers of synonyms, typos, and qualifiers (intervention names), or require cross-referencing to diverse external data sources (drug target). We therefore used a Python script to extract fields of interest into separate trials and interventions tables which were manually reviewed in Google Sheets.

Search strategy and selection criteria. We included 4 major neurodegenerative diseases: Alzheimer’s disease (AD), Parkinson’s disease (PD), frontotemporal dementia / amyotrophic lateral sclerosis (FTD/ALS) and Huntington’s disease (HD). On April 16, 2020, we searched ClinicalTrials.gov for alzheimer OR huntington OR parkinson OR als OR amyotrophic OR frontotemporal OR ftd OR ftd with start date on or before March 31, 2020, yielding 4542 NCT identifiers. Full ClinicalTrials.gov registration data for these trials were then pulled from https://clinicaltrials.gov/AllPublicXML.zip on April 16, 2020 for manual curation as described below. In order to estimate the extent to which our strategy might under-sample trials that lacked a specific disease focus, we conducted additional searches between September 16–22, 2022 for the terms dementia, movement disorders, and mild cognitive impairment. For the time period considered here, 2041/4010 (51%) of dementia trials, 1994/3545 (56%) of movement disorder trials, and 302/853 (35%) of mild cognitive impairment trials were in our original dataset. See Discussion for more details.

Trial curation. Because our research question centered on patient populations and therapeutic hypotheses, we sought to include all trials that tested an intervention hypothesized to modify the patient’s disease or symptoms, in a disease-relevant population (Fig. 1). We excluded trials lacking a therapeutic intervention, such as studies of biomarkers, diagnostics, patient data, or imaging agents, where the goal was to evaluate diagnostic or prognostic value rather than to confer therapeutic benefit. We also excluded trials that enrolled only healthy volunteers, did not study one of these four neurodegenerative diseases, or targeted the intervention to caregivers rather than patients. Finally, we excluded trials where data were incomplete or contained errors: examples included trials where inclusion required participation in a prior trial for which inclusion criteria had never been publicly posted, or where drugs listed in intervention arms did not match the title or description of the trial. We performed internet searches to identify the sector to which trial sponsors belonged (industry or “other” including academia, government, non-profits). We defined disease stage 0 (“at-risk”) as individuals at risk of disease due to genotype, age, or other risk factors. Generalizing FDA Alzheimer’s disease\(^\text{24}\) across diseases, we defined stage 1 (“molecular”) as individuals with molecular evidence of disease pathology, stage 2 (“detectable”) as individuals without functional impairment but where a sensitive neuropsychological test could discern disease-related phenotypic changes, stage 3 (“mild”) as indicating mild detectable functional impairment not yet meeting criteria for disease diagnosis, and stage 4 (“diagnosed”) as individuals diagnosed with dementia or other changes (such as motor impairment) meeting diagnostic criteria for neurodegenerative disease. For each trial, we manually determined the earliest and latest disease stage of patients eligible to enroll based on reading the inclusion and exclusion criteria. We also manually extracted the eligible score ranges on tests from these criteria, prioritizing the Mini-Mental State Examination (MMSE)\(^\text{25}\) and Hoehn and Yahr\(^\text{26}\) in instances where more than one test was used. For trials that specified only a minimum score, we inferred the maximum to be the maximum possible score; and vice versa. Trial duration was calculated as study completion date minus start date. Patient-years of enrollment were calculated as trial duration times enrollment, though we acknowledge this is an imperfect approximation, as in reality participants accrue (and withdraw) gradually rather than all participants being on board for a trial’s full duration. We used only enrollment numbers described as “Actual”; patient-years for “Anticipated” enrollment values were set to missing. The number of inclusion/exclusion criteria was calculated by counting the total number of items in numbered or bulleted lists under the headings “Inclusion Criteria” and “Exclusion Criteria”, or manually entered for 75 trials without numbered/bulleted lists.

Intervention curation. Intervention arms extracted included trials were converted to lower case and stripped of invalid text characters, yielding unique values for curation. The “intervention type” in ClinicalTrials.gov is specified inconsistently even for the exact same intervention (for instance, “deep brain stimulation” was categorized alternatively as “device”, “procedure”, “behavioral” or “other”), so we manually assigned every intervention to an intervention class: drug, device, procedure, behavioral, placebo, other, and none. We defined “drugs” as molecular interventions regardless of modality (synthetic drug, biological) or regulatory status (experimental, approved/repurposed, supplement). We considered as “behavioral” any interventions intended to alter patient behavior (exercise, diet, drug compliance) even if they utilized a device. We classified as “procedures” surgery, acupuncture, cell transplants, radiation, and changes in care protocols. In contrast, intervention arms that consisted solely of blood draws, lumbar punctures, or other events defined as “procedures” by Institutional Review Boards but not intended to confer therapeutic benefit to the patient, were classified as...
"none". We classified as “placebo” explicit placebo arms as well as standard of care, normal saline, no treatment, and similar variations. In addition, often, a single unique intervention name value (“donepezil”) would appear across dozens of trials, where sometimes it was the active therapeutic agent being tested, while at other times it served as the standard-of-care arm. For trials with > 1 intervention arm listed, if any arm was an experimental intervention while another arm was a drug that was already FDA approved for the disease in question in the year the trial occurred, we counted the latter as a placebo arm. Names of intervention arms often included information such as dose level (“riluzole 50 mg”) or formulation (“rosiglitazone xr (extended release) oral tablets”), the same drug would be assigned various generic names assigned at different stages of development (“ly3002813” is “donanemab”), and commercial names, typos, and other variations also occurred. We therefore assigned for each drug intervention arm the best generic name for the molecular entity being tested. For the 27 drugs approved by FDA for treatment of these 4 neurodegenerative diseases, years of initial approval were extracted from Drugs@FDA database searches. For the purposes of classifying experimental drugs (those not approved for these neurodegenerative diseases) as novel versus repurposed, we considered as “approved” any drug with full marketing approval in any jurisdiction worldwide. We considered only full approvals, thus aducanumab, which received Accelerated Approval in 2021, was classified as experimental. We searched several data sources to identify any available evidence as to the molecular target of each drug, and assigned gene symbols of molecular targets based on annotations in DrugBank26 (N = 993), articles in PubMed (N = 278), Alzforum (N = 244), company press releases (N = 46), information provided directly in ClinicalTrials.gov submissions (N = 19), or other (N = 18).

**Human genetic associations.** Gene-disease links established by human genetics up through the end of the study period (March 2020) were identified through manual searches of Online Mendelian Inheritance in Man (OMIM)27 for Mendelian forms of disease, and Open Targets Genetics (OTG)28 for genome-wide association studies (GWAS) of common/complex forms of disease. For GWAS loci mapping to multiple potentially causal genes, the gene with the highest locus-to-gene score28 was generally used unless additional GWAS studies of the same trait supported a different causal gene at the same locus or unless Mendelian or other compelling evidence implicated another gene (example: due to its association with familial ALS, C9orf72 was selected.
Despite ranking 2nd after MOB3B in locus-to-gene score for an ALS GWAS29, where OTG data were missing or indeterminate, the gene highlighted by the study’s original authors was used.

**Role of the funding source.** This work was supported by the National Institutes of Health (R21 TR003040 and R01 NS125255). The funder had no role in study design, analysis, interpretation, or decision to publish.

**Statistics, source code, and data availability.** Scripted extraction of ClinicalTrials.gov and DrugBank data used scripts in Python 3.8.9; data analysis and visualization were performed in R 4.2.0. All statistical tests were two-sided and nominal $P$ values less than 0.05 were considered significant. Enrichment analyses used Fisher’s exact test. Tests for temporal trends used linear regression, except for the testing of a temporal trend in disease stage (an ordinal variable), which used ordinal logistic regression (polr from the R MASS package). Loess fits were additionally used for visualization of potentially non-linear temporal trends. Error bars represent 95% confidence intervals of the mean ($\pm 1.96$ standard errors of the mean). Distributions were compared using Kolmogorov–Smirnov test, which does not assume normality. All data and source code used in this study are publicly available at http://github.com/ericminikel/nd_trials and are sufficient to reproduce the figures and statistics herein.

**Results**

**Characteristics of neurodegenerative disease trials.** Of 4542 trials returned by our search strategy, 3238 met inclusion criteria and were reviewed and annotated (Fig. 1). In order to understand the landscape of neurodegenerative disease trials, we first considered both the simple count of trials (Fig. 2A), as well as the total patient-years of enrollment (Fig. 2B) as potentially a better proxy for R&D spend, in a univariate breakdown of trials by disease area, sector, intervention type, phase, and control group status. The majority of trials were non-industry-sponsored, lacked a placebo or standard of care (SOC) arm, and for a plurality, phase was other/ unspecified. But whereas only a minority of trials were industry-sponsored (N = 1239, 38%), these trials were much larger on average, and so accounted for a majority (64%) of all patient-years. Drug interventions accounted for a majority of trials (N = 1864; 58%) but an even larger majority of patient-years (76%). In a bivariate cross-tabulation (Fig. 2C), drug trials accounted for not only the largest number of trials but were also the most intense (patient-years/trial), especially for Alzheimer’s disease, Phase III, placebo/SOC-controlled, and industry-sponsored. Overall, industry-sponsored drug trials accounted for 61% of all patient-years (Fig. 2D). The remainder—non-industry and/or non-drug trials—were highly skewed in terms of size: 34% enrolled $\leq$ 20 patients, while the 6 largest trials accounted for 33% of all patient-years, indeed, a single trial of medication adherence reminder devices30 that included PD patients comprised 13%. Industry-sponsored drug trials were less variable in size; it took the top 25 to comprise 33% of patient-years, and only 15% of trials enrolled $\leq$ 20 patients (Fig. 2D). Industry-sponsored drug trials differed from other trials in being 3.1 times more likely to have a placebo or standard of care (SOC) control arm, 2.2 times as likely to complete, and $> 100$ times as likely to have a specified phase (Fig. 2E). Industry-sponsored drug trials grew much more selective over the 2 decades considered here, with the mean number of inclusion and exclusion criteria per trial rising from ~ 9 to ~ 17 ($P = 3e$–10, linear regression; Fig. 2F), with no corresponding trend for non-industry and/or non-drug trials $P = 0.31$, linear regression; Fig. 2F). The number of inclusion and exclusion criteria rose for Phase I, II, and III trials, but not for other/unspecified phase trials (Fig. 2G).

**Disease stage of participants in trials.** Reading the inclusion and exclusion criteria, we manually annotated which disease stages, numbered 0–4 (see Methods), were eligible for each trial. 89% of trials required a diagnosis of the neurodegenerative disease in question, corresponding to disease stage 4 (Fig. 3A). Another 7.8% permitted patients with mild cognitive impairment (MCI) or an analogous level of other functional impairment, who did not yet meet diagnostic criteria for their diseases (Fig. 3A). The 2.7% of trials (N = 89) that permitted pre-symptomatic patients, corresponding to stages 0–2 (Fig. 3A), differed from other trials in several respects. Trials open to pre-symptomatic individuals were less likely to be industry-sponsored and less likely to test a drug or device; they were much more likely to test a behavioral intervention (Fig. 3B). They trended less likely to have a specified phase and had a non-significantly lower completion rate, although the proportion that included placebo/SOC arms was similar. Trials open to pre-symptomatic individuals were significantly longer on average ($P = 0.0004$, Kolmogorov–Smirnov test; Fig. 3C) and trended slightly larger in enrollment, though the difference was not significant ($P = 0.09$, Kolmogorov–Smirnov test). The proportion of trials enrolling earlier disease stages rose slightly in recent years ($P < 1e$–10, ordinal logistic regression), although in absolute terms, the proportion of trials enrolling at stages < 4 rose only from 8% in the first 4 years of the data to 15% in the final 4 years of data (Fig. 3D). We also examined whether quantitative measures of impairment changed over time, regardless of nominal disease stage. A majority of trials (57%, N = 1833/3238) used a disease severity scale as one inclusion or exclusion criterion, most often the Mini-Mental State Examination4 (MMSE; 28%, N = 911) or Hoehn & Yahr25 (23%; N = 757). For MMSE, on average, the maximum (least impaired) admissible score rose from 25.6 in 2000 to 27.6 in 2020 ($P = 2e$–5, linear regression), while the minimum (most impaired) admissible score rose from 13.6 to 17.7 ($P = 1e$–5; Fig. 3E). Thus, trials using MMSE focused on less impaired patients over time, and because the exclusion of too-advanced patients became stricter more rapidly than the inclusion of less advanced patients, the size of the eligible window shrunk over time. Analogously, for Hoehn & Yahr, where higher scores correspond to more advanced disease, the average minimum (least impaired) admissible score dropped from 1.6 to 1.2 over the 20 years ($P = 0.002$), while the average maximum (most impaired) limit dropped from 3.8 to 3.1 ($P = 6e$–10), again reflecting a shift towards less impaired patients together with a shrinking of the eligible window (Fig. 3F).
Therapeutic hypotheses tested in drug trials. We identified $N = 748$ unique molecular entities (including unique combinations) tested across $N = 1864$ drug trials. Based on regulatory status and molecular target(s), we classified these trials into 7 categories (Fig. 4A). There exist 27 drugs that have full approval and are labeled by FDA specifically for the treatment of the neurodegenerative diseases considered here. Trials in support of these approved drugs, for their approved indications, comprised 18% of patient-years. Only a minority, however, were launched in years prior to FDA approval (Fig. 4A). Trials of these same molecular entities occurring after first approval—for example, those seeking to expand the label, meet regulators’ requirements in other countries, understand drug effects on additional endpoints, or test new formulations or delivery routes of the same molecular entity—outnumbered the trials preceding initial approval by a factor of $>4$ (Fig. 4B). Indeed, donepezil, whose approval for Alzheimer’s (1996) pre-dates the time range considered here, was the single most intensely studied drug in this entire dataset ($N = 55$ trials). For each of the drugs approved for these diseases prior to 2017, there were at least as many post-approval as pre-approval trials (Fig. 4B).

Another 34% of patient-years were spent on trials of either repurposed drugs, new drugs for established targets (targets with a drug approved for any disease), or combinations of 2 or more therapies where all are either approved drugs or supplements. In all, trials explored 272 different targets of approved drugs (Fig. 4C). Of repurposing efforts, 55 trials used a drug approved for one neurodegenerative disease and tested its efficacy

Figure 2. Characteristics of neurodegenerative disease clinical trials. (A) Univariate count of trials by disease, sponsor, intervention class, phase, or placebo/SOC control status. (B) Total Univariate total of patient-years (see Methods) by the same variables. (C) Bivariate cross-tabulation of number of trials and patient-years. Intensity (patient-years per trial) is expressed as a color palette from transparent yellow to opaque blue; number of trials is expressed as the size of each circle. (D) Pie chart of patient-years of enrollment, with industry drug trials shown in 3 alternating shades of pink and all other trials in 3 alternating shades of green. Each wedge represents one trial, and trials are sorted by number of patient-years. (E) Barplot representation of contingency tables for whether trials are (purple) or are not (gray) placebo/SOC-controlled (top), completed (middle), or have a specified phase (bottom) depending on whether they are industry-sponsored drug trials (right) or other (left). (F–G) Mean total number of inclusion and exclusion criteria per trial as a function of (F) industry-sponsored drug trials versus other, and (G) phase. Loess curves were fit on the raw individual values, but due to the large number of trials, individual values are not shown; instead the average for each year is shown as a semitransparent horizontal bar. Statistical significance was evaluated by linear regression, see Results text.
in a different neurodegenerative disease (for example, the Alzheimer’s drug memantine was trialed for Parkinson’s, Huntington’s, and FTD/ALS). Ten times as many trials (N = 557), however, tested drugs approved for other indications, chiefly in neurology (N = 195), metabolic (N = 72), and cardiovascular disease (N = 47); the most studied repurposed drug was botulinum toxin A (N = 17).

Trials comprising 48% of patient-years tested novel therapeutic hypotheses—molecular entities not yet approved and whose molecular targets are either unknown, or are not yet targeted by any other approved drug. Curating associations from both Mendelian forms and genome-wide association studies for these 4 diseases (see Methods), we identified N = 101 gene-disease pairs linked by human genetic evidence (Fig. 4D). We asked which of these therapeutic hypotheses had been tested clinically. Approximately three-quarters (429/577) of trials of novel therapeutic hypotheses lacked direct human genetic association implicating the target in the disease.
The two most intensely studied targets in this group were those with functional evidence for disease relevance (MAPT and BACE1 in AD, N = 23 trials each). For the majority of trials in this category (72%, N = 307), however, we were unable to identify any known molecular target. The remaining (148/577) trials tested N = 16 target-indication pairs backed by human genetics. Their share of all drug trials did not increase over time (P = 0.59, linear regression; Fig. 4E) despite the increased number of genetic associations reported (Fig. 4D). Instead, the only two categories of trial whose share increased significantly were repurposed targets and novel hypotheses without genetic support (P = 0.02 and 0.008 respectively). For 14 genetically supported targets, the first clinical trial followed the discovery of the genetic association, with a mean lag time of 13 years, and a minimum lag time of 5 years (TREM2; Fig. 4F). All (4/4) targets with both a genetic association and a pre-existing approved drug had been trialed (Fig. 4C): 1 with a novel drug (CD33 in AD), 2 apparently coincidentally (BST1 and SCN2A in PD) and 1 with a repurposed drug selected at least in part based on genetic evidence (ACE in AD).

Overall, trials of genetically supported hypotheses only comprised half as many patient-years as novel hypotheses without genetic support (Fig. 4A), and no genetically supported agent was studied as intensely as gingko biloba, to which the two largest trials in the dataset were devoted. Investment in genetically supported target-indication pairs was highly skewed, with 68% of trials and 84% of patient-years devoted to targeting Aβ (APP) in Alzheimer’s disease (Fig. 4G). Just 3 trials tested genetically supported hypotheses in a preventive paradigm, enrolling individuals at disease stages 0–2: A435, API36, and DIAN-TU37, all of which tested Aβ antibodies.

**Discussion**

Here we used 2 decades of clinical trial registration data to analyze the characteristics of trials in 4 major neurodegenerative diseases. We were motivated by evidence from other disease areas showing that drug programs whose therapeutic hypotheses are supported by human genetic associations enjoy doubled success rates17. We analyzed trial types, disease stages and therapeutic hypotheses being tested to assess to what degree this opportunity has been utilized in major neurodegenerative diseases.

Our study has several limitations. By design, our search and curation strategy focused on four specific neurodegenerative diseases. Trials on other neurodegenerative diseases, or trials that lacked a specific disease focus, may not be included here. Our dataset included about half of trials matching search terms “dementia” and “movement disorders” but only a third for “mild cognitive impairment”, which may suggest that our search strategy leads to undersampling of early symptomatic stage trials. Other limitations include non-exhaustive capture of trials by ClinicalTrials.gov, limited amount and types of data available in trial registrations, human error in the curation process, and the inherently retrospective nature of the analysis.

Pre-symptomatic intervention offers the promise of preserving quality of life before patients are impaired, but is very rare in clinical trials. To the extent that trial enrollment has shifted toward less impaired patients over the past 2 decades, this has come at the expense of screening more patients out, with proliferating inclusion and exclusion criteria and narrower acceptable score ranges. Trials in pre-symptomatic patients remain vanishingly rare, comprising just 2.7% of all trials, and this small fraction is enriched for behavioral interventions and depleted for drug trials and industry sponsorship. Industry-sponsored drug trials, despite representing a minority of all trials in our dataset, accounted for a majority of patient-years of enrollment, and were much more likely than other trials to complete, to have placebo/SOC control arms, and to have a specified trial phase. It is reasonable to conclude that these industry-sponsored drug trials likely represent a large majority of the “shots on goal” for well-powered demonstrations of clinical efficacy. Such trials have very seldom aimed at pharmacologic prevention of neurodegenerative disease.

Trials testing hypotheses rooted in human genetics are a minority and have not become more common despite a proliferation of genetic associations. More common types of trials include those of agents without any known molecular target, post-approval trials of approved symptom-managing drugs, and repurposing trials of drugs approved for other indications. Across the pharmacopoeia, of the 729 targets corresponding to drugs approved for any condition, 272 (37%) were tested for neurodegenerative disease, while of 101 hypotheses nominated by human genetics, just 16 were tested. The average time from genetic discovery to first human trial was more than a decade, and the majority of trials and an even larger majority of patient-years focused on Aβ in AD, with limited attention paid to other potential targets.

Our findings suggest the risk of a missed opportunity. Most of the genetic studies that have nominated new molecular targets are familial linkage or case–control studies, and thus are best suited to identify the initial triggers of disease. There appears to be an imperfect overlap between the molecular drivers of neurodegenerative disease initiation and the molecular drivers of subsequent progression38–41. For some targets nominated by these types of genetic studies, pre-symptomatic populations might represent the best, or in some cases only, opportunity for efficacy. Yet trials are conducted overwhelmingly in symptomatic patients. On one hand, GWAS of disease progression rates may help to identify targets more likely to yield efficacy in symptomatic patients. Meanwhile additional investment in well-powered, well-controlled trials at earlier disease stages may be needed to realize the potential of targets involved in disease initiation, and ultimately improve our odds of not only extending life, but extending quality of life.
Figure 4. Therapeutic hypotheses tested in drug trials. (A) Area-scaled barplot of 7 categories of drug interventions tested. The length of each rectangle on the x axis is the number of trials; thickness on the y axis is proportional to the number of patient-years per trial. Thus the total area occupied by each rectangle is proportional to the total patient-years invested in each category, for which percentages of the total are overlaid in white text. (B) Barplot of number of trials per year for drugs FDA approved for the treatment of the indicated disease before (cyan) and after (gray) initial FDA approval. Trials of these same drugs in other neurodegenerative diseases, for which they are not yet labeled by FDA, are not included in this plot; trials where these drugs served as SOC arms are also excluded. Black triangles indicate years of first FDA approval; approvals prior to 2000 are left-aligned. (C) Proportional area Euler diagram of genes that encode targets of drugs approved for any indication (gray), targets tested in neurodegenerative disease clinical trials in this dataset (red), or targets supported by human genetic evidence (yellow). (D) Stacked area plot of cumulative number of genes associated to these 4 diseases by year. Association of ACE to AD is counted in 1999 acknowledging candidate gene studies which replicated by GWAS in 2018. (E) Stacked area plot of categories of trials as defined in (A) by year. (F) Scatterplot of genetically supported target-indication pairs pursued in drug trials, displayed as year of first reported genetic association (x axis) versus year of first trial in the genetically linked neurodegenerative disease (y axis), color-coded by disease. *Gamma secretase is represented here by PSEN1; members PSEN2 and APH1B also have genetic association to AD risk. (H) Barplot of number of trials for each genetically supported target, in its genetically supported indication, tested clinically.

Received: 21 July 2022; Accepted: 4 October 2022
Published online: 21 October 2022

References
1. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7, e105–e125 (2022).
2. Hay, M., Thomas, D. W., Craighead, J. L., Economides, C. & Rosenthal, J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40–51 (2014).
3. Wong, C. H., Sieh, K. W. & Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics 20, 273–286 (2019).
4. Thomas, D. et al. Clinical Development Success Rates and Contributing Factors 2011–2020. 34 https://go.bio.org/rs/490-EHZ-999/images/ ClinicalDevelopmentSuccessRates2011_2020.pdf (2021).
5. McDate, E. & Bateman, R. J. Stop Alzheimer's before it starts. Nature 547, 153–155 (2017).
6. Livingston, G. et al. Alzheimer's disease and related disorders: research priorities and potential interventions for improving lives today and tomorrow. Lancet 390, 2673–2743 (2017).
7. U.S. Food and Drug Administration. Early Alzheimer's Disease: Developing Drugs for Treatment. Draft Guidance for Industry. https://www.fda.gov/media/119903/download (2018).
8. Valla, S. M. The patient-scientist's mandate. N. Engl. J. Med. 382, 107–109 (2020).
9. Valla, S. M., Minikid, E. V., Schreiber, S. L. & Lander, E. S. Towards a treatment for genetic prion disease: Trials and biomarkers. Lancet Neurol. 19, 361–368 (2020).
10. Berg, D. et al. Path to Parkinson disease prevention: Conclusion and outlook. Neurology 99, 76–83 (2022).
11. Benatar, M. et al. Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: The ATLAS study. Neurotherapeutics. https://doi.org/10.1007/s13311-022-01237-4 (2022).
12. Cummings, J. et al. Alzheimer's disease drug development pipeline: 2022. Alzheimers Dement (N Y) 8, e12295 (2022).
13. McFarthing, K., Rafallof, G., Baptist, M. A. S., Wyse, R. K. & Stott, S. R. W. Parkinson's disease drug therapies in the clinical trial pipeline: 2021 update. J. Parkinsons Dis. 11, 891–903 (2021).
14. Vallabh, S. M., Alberici, A., Cairns, N. J., Romano, M. & Buratti, E. From basic research to the clinic: Innovative therapies for ALS and FTD in the pipeline. Mol. Neurodegener. 15, 31 (2020).
15. Estevez-Fraga, C., Rodrigues, F. B., Tabrizi, S. J. & Wild, E. J. Huntington's disease clinical trials corner: April 2022. J. Huntington Dis. 11, 105–118 (2022).
16. Plenge, R. M., Scinich, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. Nat. Rev. Drug Dis. 12, 381–394 (2013).
17. Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856–860 (2015).
18. King, E. A., Davis, J. W. & Degner, J. F. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 15, e1008489 (2019).
19. Miller, J. E., Wilenszick, M., Ritcey, N., Ross, J. S. & Mello, M. M. Measuring clinical trial transparency: An empirical analysis of newly approved drugs and large pharmaceutical companies. BMJ Open 7, e017917 (2017).
20. Lassman, S. M., Shopsheer, O. M., Jazic, I., Ulrich, J. & Francer, J. Clinical trial transparency: A reassessment of industry compliance with clinical trial registration and reporting requirements in the United States. BMJ Open 7, e015110 (2017).
21. Ross, J. S., Mulvey, G. K., Hines, E. M., Nissen, S. E. & Krumholz, H. M. Trial publication after registration in ClinicalTrials.Gov: A cross-sectional analysis. PLoS Med. 6, e1000144 (2009).
22. Anderson, M. L. et al. Compliance with clinical trial registration and reporting requirements in the United States. BMJ Open 7, e015110 (2017).
23. Ross, J. S. et al. Publication of NIH funded trials registered in ClinicalTrials.gov: Cross sectional analysis. BMJ 344, d7292 (2012).
24. Folstein, M. F., Folstein, S. E. & McHugh, P. R. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189–198 (1975).
25. Hoehn, M. M. & Yahr, M. D. Parkinsonism: Onset, progression and mortality. Neurology 17, 427–442 (1967).
26. Wishart, D. S. et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074–D1082 (2018).
27. Amberger, J. S., Bocchini, C. A., Scott, A. F. & Hamosh, A. OMIM.org: Leveraging knowledge across phenotype-gene relationships. Nucleic Acids Res. 47, D1038–D1043 (2019).
28. Mountjoy, E. et al. An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci. Nat. Genet. 53, 1527–1533 (2021).
29. Nicolas, A. et al. Genome-wide analyses identify KIF5A as a Novel ALS gene. Neuron 97, 1268-1283.e6 (2018).
30. Choudhry, N. K. et al. Effect of reminder devices on medication adherence: The REMIND randomized clinical trial. JAMA Intern. Med. 177, 624–631 (2017).
31. Kehoe, P. G. et al. Variation in DCP1, encoding ACE, is associated to susceptibility to Alzheimer and Huntington disease (2018).
33. Brakedal, B. et al. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease. Cell Metab. 34, 396–407.e6 (2022).

34. Wharton, W. et al. The effects of ramipril in individuals at risk for Alzheimer’s disease: Results of a pilot clinical trial. J. Alzheimers Dis. 32, 147–156 (2012).

35. Sperling, R. A. et al. The A4 study: Stopping AD before symptoms begin?. Sci. Transl. Med. 6, 228fs13 (2014).

36. Tariot, P. N. et al. The Alzheimer’s Prevention Initiative Autosomal-Dominant Alzheimer’s Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer’s disease, including a placebo-treated noncarrier cohort. Alzheimers Dement (N Y) 4, 150–160 (2018).

37. Salloway, S. et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease. Nat. Med. 27, 1187–1196 (2021).

38. Moss, D. J. H. et al. Identification of genetic variants associated with Huntington’s disease progression: A genome-wide association study. Lancet Neurol. 16, 701–711 (2017).

39. Leonenko, G. et al. Genetic risk for Alzheimer disease is distinct from genetic risk for amyloid deposition. Ann. Neurol. 86, 427–435 (2019).

40. Jones, E. et al. Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: A genome-wide association study. Lancet Neurol. 19, 840–848 (2020).

41. Liu, G. et al. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson’s disease. Nat. Genet. 53, 787–793 (2021).

Author contributions
S.M.V. and E.V.M. conceived and designed the study. M.A.M., S.M.V., and E.V.M. curated the dataset. E.V.M. analyzed the data and drafted the manuscript. M.A.M., S.M.V., and E.V.M. reviewed, edited, and approved the final manuscript.

Funding
Funding was provided by National Institutes of Health (R21 TR003040 and R01 NS125255).

Competing interests
MAM reports no disclosures. SMV has received speaking fees from Ultragenyx, Illumina, and Biogen, consulting fees from Invitae, and research support in the form of unrestricted charitable contributions from Ionis, Gate, and Charles River. EVM has received consulting fees from Deerfield and research support in the form of unrestricted charitable contributions from Ionis, Gate, and Charles River.

Additional information
Correspondence and requests for materials should be addressed to E.V.M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022